Drug Profile
TQ B3234
Alternative Names: TQ-B3234Latest Information Update: 28 Dec 2023
Price :
$50
*
At a glance
- Originator Chia Tai Tianqing Pharmaceutical Group
- Class Antineoplastics
- Mechanism of Action MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Second-line therapy or greater) in China (PO)
- 11 Nov 2021 TQ B3234 is still in phase I trials for Solid tumors in China as of November 2021 (NCT05107037)
- 11 Nov 2021 Chia Tai Tianqing Pharmaceutical Group plans a phase I trial for Neurofibromatosis-1 (In the elderly) in China (PO) (NCT05107037)